Federal Register / Vol. 80, No. 53 / Thursday, March 19, 2015 / Notices 14401 

A. Progress Reports 

Program progress reports are required 

semi-annually within 30 days after the 

budget period ends. These reports must 

include a brief comparison of actual 

accomplishments to the goals 

established for the period, or, if 

applicable, provide sound justification 

for the lack of progress, and other 

pertinent information as required. A 

final report must be submitted within 90 

days of expiration of the budget/project 

period. 

B. Financial Reports 

Federal Financial Report FFR (SF– 

425), Cash Transaction Reports are due 

30 days after the close of every calendar 

quarter to the Payment Management 

Services, HHS at: http://

www.dpm.psc.gov. It is recommended 

that the applicant also send a copy of 

the FFR (SF–425) report to the Grants 

Management Specialist. Failure to 

submit timely reports may cause a 

disruption in timely payments to the 

organization. 

Grantees are responsible and 

accountable for accurate information 

being reported on all required reports: 

The Progress Reports and Federal 

Financial Report. 

C. Federal Subaward Reporting System 

(FSRS) 

This award may be subject to the 

Transparency Act subaward and 

executive compensation reporting 

requirements of 2 CFR part 170. 

The Transparency Act requires the 

OMB to establish a single searchable 

database, accessible to the public, with 

information on financial assistance 

awards made by Federal agencies. The 

Transparency Act also includes a 

requirement for recipients of Federal 

grants to report information about firsttier subawards and executive 

compensation under Federal assistance 

awards. 

IHS has implemented a Term of 

Award into all IHS Standard Terms and 

Conditions, NoAs and funding 

announcements regarding the FSRS 

reporting requirement. This IHS Term of 

Award is applicable to all IHS grant and 

cooperative agreements issued on or 

after October 1, 2010, with a $25,000 

subaward obligation dollar threshold 

met for any specific reporting period. 

Additionally, all new (discretionary) 

IHS awards (where the project period is 

made up of more than one budget 

period) and where: 1) the project period 

start date was October 1, 2010 or after 

and 2) the primary awardee will have a 

$25,000 subaward obligation dollar 

threshold during any specific reporting 

period will be required to address the 

FSRS reporting. For the full IHS award 

term implementing this requirement 

and additional award applicability 

information, visit the DGM Grants 

Policy Web site at: https://www.ihs.gov/ 

dgm/index.cfm?module=dsp_dgm_

policy_topics. 

Telecommunication for the hearing 

impaired is available at: TTY (301) 443– 

6394. 

VII. Agency Contacts 

1. Questions on the programmatic 

issues may be directed to: Ms. Patricia 

Spotted Horse, Program Analyst, Office 

of Direct Service and Contracting Tribes, 

Indian Health Service, 801 Thompson 

Avenue, Suite 220, Rockville, MD 

20852–1609, Telephone: (301) 443– 

1104, Email: Patricia.SpottedHorse@

ihs.gov. 

2. Questions on grants management 

and fiscal matters may be directed to: 

Mr. Pallop Chareonvootitam, Grants 

Management Specialist, Office of 

Management Services, Division of 

Grants Management, 801 Thompson 

Avenue, TMP Suite 360, Rockville, MD 

20852–1609, Telephone: (301) 443– 

5204, Fax: (301) 443–9602, Email: 

Pallop.Chareonvootitam@ihs.gov. 

3. Questions on systems matters may 

be directed to: Mr. Paul Gettys, Grant 

Systems Coordinator, Office of 

Management Services, Division of 

Grants Management, 801 Thompson 

Avenue, TMP Suite 360, Rockville, MD 

20852, Phone: (301) 443–2114; or the 

DGM main line (301) 443–5204, Fax: 

(301) 443–9602, Email: Paul.Gettys@

ihs.gov. 

VIII. Other Information 

The PHS strongly encourages all 

cooperative agreement and contract 

recipients to provide a smoke-free 

workplace and promote the non-use of 

all tobacco products. In addition, Public 

Law 103–227, the Pro-Children Act of 

1994, prohibits smoking in certain 

facilities (or in some cases, any portion 

of the facility) in which regular or 

routine education, library, day care, 

health care, or early childhood 

development services are provided to 

children. This is consistent with the 

HHS mission to protect and advance the 

physical and mental health of the 

American people. 

Dated: March 12, 2015. 

Robert G. McSwain, 

Acting Director, Indian Health Service. 

[FR Doc. 2015–06353 Filed 3–18–15; 8:45 am] 

BILLING CODE 4165–16–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Eye Disease Mechanisms and 

Models. 

Date: April 14, 2015. 

Time: 8:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Alessandra C Rovescalli, 

Ph.D., Scientific Review Officer, National 

Institutes of Health, Center for Scientific 

Review, 6701 Rockledge Drive, Rm. 5205 

MSC7846, Bethesda, MD 20892, (301) 435– 

1021, rovescaa@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Myalgic 

Encephalomyelitis/Chronic Fatigue 

Syndrome. 

Date: April 14, 2015. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Lynn E Luethke, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5166, 

MSC 7844, Bethesda, MD 20892, (301) 806– 

3323, luethkel@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; SEP: 4D 

Nucleome Network Organizational Hub. 

Date: April 15, 2015. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Allen Richon, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 


Rmajette on DSK2VPTVN1PROD with NOTICES
14402 Federal Register / Vol. 80, No. 53 / Thursday, March 19, 2015 / Notices 

MSC 7892, Bethesda, MD 20892, 301–379– 

9351, allen.richon@nih.hhs.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR14–247: 

Pharmacogenetics, Pharmacoepigenetics and 

Personalized Medicine in Children. 

Date: April 16, 2015. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Elaine Sierra-Rivera, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1779, riverase@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Ocular Diseases Pathophysiology 

and Therapeutic Approaches. 

Date: April 16, 2015. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Alessandra C Rovescalli, 

Ph.D., Scientific Review Officer, National 

Institutes of Health, Center for Scientific 

Review, 6701 Rockledge Drive, Rm. 5205 

MSC7846, Bethesda, MD 20892, (301) 435– 

1021, rovescaa@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–13– 

190: Detection of Pathogen Induced Cancer. 

Date: April 17, 2015. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Gagan Pandya, Ph.D., 

Scientific Review Officer, National Institutes 

of Health, Center for Scientific Review, 6701 

Rockledge Drive, Rm. 3200, MSC 7808, 

Bethesda, MD 20892, 301–435–1167, 

pandyaga@mai.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 13, 2015. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06268 Filed 3–18–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications, 

contract proposal, and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the grant applications or 

contract proposal, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Clinical Research in HIV/HLB Diseases. 

Date: April 13, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Dupont Circle Hotel, 1500 New 

Hampshire Avenue NW., Washington, DC 

20036. 

Contact Person: Stephanie L Constant, 

Ph.D. Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7189, Bethesda, MD 20892, 301– 

443–8784 constantsl@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Improving Red Blood Cells for Transfusion. 

Date: April 13, 2015. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Room 7198, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Kristin Goltry, Ph.D. 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7198, Bethesda, MD 20892, 301–435–0297, 

goltrykl@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: March 13, 2015. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06269 Filed 3–18–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0620] 

An Interactive Discussion on the 

Clinical Considerations of Risk in the 

Postmarket Environment; Public 

Workshop; Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public workshop; 

request for comments. 

The Food and Drug Administration 

(FDA) is announcing a public workshop 

entitled ‘‘Clinical Considerations of Risk 

in the Postmarket Environment.’’ The 

purpose of this workshop is to provide 

a forum for an interactive discussion on 

assessing changes in medical device risk 

as quality and safety situations arise in 

the postmarket setting when a patient, 

operator, or member of the public uses 

the device. FDA is interested in 

obtaining input from stakeholders about 

assessing risk postmarket when new 

hazards develop in the postmarket 

setting that were not present or not 

known at the time of clearance or 

approval or hazards were anticipated, 

but harm occurs at an unexpected rate 

or in unexpected populations or use 

environments. Comments and 

suggestions generated through this 

workshop will facilitate the assessment 

of risk in postmarket quality and safety 

situations. 

Date and Time: The public workshop 

will be held on April 21, 2015, from 

8:30 a.m. to 5 p.m. 

Location: The public workshop will 

be held at FDA’s White Oak Campus, 

10903 New Hampshire Ave., Building 

31 Conference Center, the Great Room 

(Rm. 1503), Silver Spring, MD 20993– 

0002. Entrance for the public meeting 

participants (non-FDA employees) is 

through Building 1 where routine 

security check procedures will be 

performed. For parking and security 

information, please refer to: http://

www.fda.gov/AboutFDA/

WorkingatFDA/BuildingsandFacilities/

WhiteOakCampusInformation/

ucm241740.htm. 

Contact Person: Jean M. Cooper, 

Center for Devices and Radiological 

Health, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 66, 

Rm. 5540, Silver Spring, MD 20993, 

301–796–6141, email: Jean.Cooper@

fda.hhs.gov. 

Registration: Registration is free and 

available on a first-come, first-served 

basis. Persons interested in attending 

this public workshop must register 


Rmajette on DSK2VPTVN1PROD with NOTICES